Search company, investor...

Predict your next investment

Boehringer Ingelheim company logo
Corporation
boehringer-ingelheim.com

Investments

12

Portfolio Exits

8

Funds

1

Partners & Customers

10

About Boehringer Ingelheim

Boehringer Ingelheim is a global pharmaceutical company that focuses on prescription medicines, consumer health care, chemicals, biopharmaceuticals, and animal health.

Headquarters Location

Binger Strasse 173

Ingelheim am Rhein, 55216,

Germany

+49 - 6132 - 77 0

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Boehringer Ingelheim News

IBD patients with higher intra-abdominal fat less likely to respond to biologic therapy

Aug 16, 2023

Disclosures: Melmed reports consulting for AbbVie, Arena, Boehringer Ingelheim, Bristol Myers Squibb/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Shionogi, Takeda and TechLab; and receiving research funding from Pfizer. Yarur reports consulting for Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Procise Inc. and Takeda. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio This association could result from differences in inflammatory cytokine expression. Patients with inflammatory bowel disease and a higher percentage of intra-abdominal visceral adipose tissue were less likely to achieve corticosteroid-free remission when treated with biologics, according to data in Gastroenterology. “Even though biologic medications have significantly improved outcomes for our patients with Crohn’s disease or ulcerative colitis, some people do not respond well to these therapies,” Andres J. Yarur, MD, study author and associate professor of gastroenterology and hepatology at Cedars-Sinai in Los Angeles, said in a related press release. “In our study, we found that the patients with higher amounts of internal abdominal fat were less likely to improve and experience remission from their disease.” Data derived from: Yarur AJ, et al. Gastroenterology. 2023;doi:10.1053/j.gastro.2023.06.036. Yarur and colleagues conducted a prospective, observational cohort study to assess the association between intra-abdominal visceral adipose tissue (IA-VAT) and response to three biologics. Researchers enrolled 141 adult patients with IBD who received standard dosing of infliximab (n = 52), vedolizumab (n = 46) or ustekinumab (n = 43) and compared them with 51 healthy controls. Participants were evaluated at baseline, after biologic induction (week 14 for infliximab and vedolizumab and week 16 for ustekinumab) and at week 30 of maintenance therapy for infliximab and vedolizumab and week 32 for ustekinumab. Lean mass, total adipose tissue and IA-VAT was measured at baseline. The primary outcome was corticosteroid-free deep remission (SFDR) at week 14 or 16; secondary outcomes included SFDR at week 30 or 32 and endoscopic remission at weeks 30 through 46. According to study results, 34% of participants achieved SFDR at week 14 or 16 and 40% at week 30 or 32. In the infliximab group, 32.7% achieved SFDR at week 14 and 46.3% at week 30, while 39.1% and 41.4% achieved SFDR at those time points in the vedolizumab group. In the ustekinumab group, 30.2% achieved SFDR at week 16 and 28.5% at week 32. Multivariable analysis showed higher IA-VAT (OR per percent increase = 0.4; 95% CI, 0.16-0.98), previous biologic exposure (OR = 3.499; 95% CI, 1.43-8.53) and drug levels in the highest two quartiles for each biologic (OR = 2.97; 95% CI, 1.2-7.32) were independently linked with failure to achieve SFDR at week 14 or 16. Further, failure to achieve SFDR at week 30 or 32 was independently associated with drug levels in the two lowest quartiles for each biologic (OR = 0.26; 95% CI, 0.1-0.68) and high IA-VAT (OR = 0.25; 95% CI, 0.09-0.64). Results also showed that high IA-VAT correlated with higher interleukin-6 and tumor necrosis factor among non-responders at baseline compared with responders and those with low IA-VAT. Researchers reported no differences in drug pharmacokinetics and microbiota diversity between the high and low IA-VAT groups. “We found that higher visceral adiposity was associated with higher levels of pro-inflammatory cytokines, suggesting that fat tissue promotes inflammation, the opposite of what we want, and increases resistance to biologic drug therapy,” Gil Y. Melmed, MD, MS, study author and director of IBD clinical research at Cedars-Sinai, said in the release. Yarur added: “We need to investigate drugs with different mechanisms of action, especially other small molecules, to see if our findings hold. As the prevalence of obesity and metabolic syndrome increases in our population, we need to find interventions that would improve the body composition of these IBD patients who are not currently helped by these biologic treatments.” Reference:

Boehringer Ingelheim Investments

12 Investments

Boehringer Ingelheim has made 12 investments. Their latest investment was in CowTribe as part of their Corporate Minority on October 05, 2022.

CBI Logo

Boehringer Ingelheim Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/5/2022

Corporate Minority

CowTribe

Yes

3

1/1/2021

Biz Plan Competition

Thymmune Therapeutics

Yes

1

8/6/2020

Series A

T-Knife

$78.17M

Yes

6

4/15/2019

Corporate Minority

Subscribe to see more

Subscribe to see more

10

6/12/2015

Grant - V

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/5/2022

1/1/2021

8/6/2020

4/15/2019

6/12/2015

Round

Corporate Minority

Biz Plan Competition

Series A

Corporate Minority

Grant - V

Company

CowTribe

Thymmune Therapeutics

T-Knife

Subscribe to see more

Subscribe to see more

Amount

$78.17M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

1

6

10

10

Boehringer Ingelheim Portfolio Exits

8 Portfolio Exits

Boehringer Ingelheim has 8 portfolio exits. Their latest portfolio exit was Boehringer Ingelheim - Brazil Buscopan Production Operation on May 10, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/10/2022

Divestiture

Boehringer Ingelheim - Brazil Buscopan Production Operation

$99M

2

3/27/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/14/2018

Asset Sale

Subscribe to see more

$99M

Subscribe to see more

10

2/1/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

1/19/2017

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/10/2022

3/27/2020

12/14/2018

2/1/2018

1/19/2017

Exit

Divestiture

Acquired

Asset Sale

Acquired

Divestiture

Companies

Boehringer Ingelheim - Brazil Buscopan Production Operation

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Boehringer Ingelheim Acquisitions

12 Acquisitions

Boehringer Ingelheim acquired 12 companies. Their latest acquisition was Trutino Biosciences on June 14, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/14/2022

Seed / Angel

$99M

$1.5M

Acquired

7

9/21/2021

Other

$99M

$1.25M

Acquired

2

12/10/2020

Series C

$99M

$65.74M

Acquired

4

12/9/2020

Subscribe to see more

$99M

Subscribe to see more

10

7/27/2020

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/14/2022

9/21/2021

12/10/2020

12/9/2020

7/27/2020

Investment Stage

Seed / Angel

Other

Series C

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$1.5M

$1.25M

$65.74M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

7

2

4

10

10

Boehringer Ingelheim Fund History

1 Fund History

Boehringer Ingelheim has 1 fund, including Boehringer Ingelheim Venture Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/31/2010

Boehringer Ingelheim Venture Fund

Early-Stage Venture Capital

Closed

$135.3M

1

Closing Date

3/31/2010

Fund

Boehringer Ingelheim Venture Fund

Fund Type

Early-Stage Venture Capital

Status

Closed

Amount

$135.3M

Sources

1

Boehringer Ingelheim Partners & Customers

10 Partners and customers

Boehringer Ingelheim has 10 strategic partners and customers. Boehringer Ingelheim recently partnered with Zealand Pharma on May 5, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

5/12/2023

Partner

Denmark

Health News Roundup: WHO declares end to mpox public health emergency; FDA advisers weigh Sarepta's Duchenne gene therapy and more

Factbox-Drugmakers bulk up with bets on weight-loss treatments Zealand Pharma and partner Boehringer Ingelheim on Wednesday announced positive trial data for their weight-loss treatment and joined the race for a share of a global obesity drug market that is expected to touch $ 100 billion within a decade .

1

5/10/2023

Partner

Israel

07:00 EDT Healthy.io Announces Collaboration with Boehringer Ingelheim to Increase Access to Testing for Kidney Disease

Healthy.io partners with leading health plans to integrate Minuteful ™ across their populations .

2

5/8/2023

Partner

United States

Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases

BOSTON , May 8 , 2023 / PRNewswire / -- Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity , today announced a new partnership with Boehringer Ingelheim .

7

5/5/2023

Partner

Australia

Subscribe to see more

Subscribe to see more

10

4/21/2023

Partner

Switzerland

Subscribe to see more

Subscribe to see more

10

Date

5/12/2023

5/10/2023

5/8/2023

5/5/2023

4/21/2023

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

Denmark

Israel

United States

Australia

Switzerland

News Snippet

Health News Roundup: WHO declares end to mpox public health emergency; FDA advisers weigh Sarepta's Duchenne gene therapy and more

Factbox-Drugmakers bulk up with bets on weight-loss treatments Zealand Pharma and partner Boehringer Ingelheim on Wednesday announced positive trial data for their weight-loss treatment and joined the race for a share of a global obesity drug market that is expected to touch $ 100 billion within a decade .

07:00 EDT Healthy.io Announces Collaboration with Boehringer Ingelheim to Increase Access to Testing for Kidney Disease

Healthy.io partners with leading health plans to integrate Minuteful ™ across their populations .

Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases

BOSTON , May 8 , 2023 / PRNewswire / -- Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity , today announced a new partnership with Boehringer Ingelheim .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

7

10

10

Boehringer Ingelheim Team

20 Team Members

Boehringer Ingelheim has 20 team members, including current President, Randolph Legg.

Name

Work History

Title

Status

Randolph Legg

President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Randolph Legg

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.